Symbols / MNKD $2.73 -1.44%
MNKD Chart
About
MannKind Corporation, a biopharmaceutical company, focuses on the provision of various solutions for transforming chronic disease care. It develops and commercializes treatments that address serious unmet medical needs, including diabetes, pulmonary hypertension, and fluid overload in heart failure and chronic kidney disease. It offers Afrezza inhalation powder, an inhaled insulin used to improve glycemic control in adults with diabetes; and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults. Its products also include Tyvaso DPI for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease; FUROSCIX, a furosemide injection to treat fluid buildup in patients with chronic heart failure or chronic kidney disease. The company's pipeline of treatments for orphan lung diseases include MNKD-201, a dry-powder formulation of nintedanib for the treatment of idiopathic pulmonary fibrosis and MNKD-701. It has collaboration and license agreement with United Therapeutics Corporation for development, regulatory, and commercial activities of Tyvaso DPI; and collaboration agreement with Thirona to evaluate the therapeutic for the treatment of pulmonary fibrosis. MannKind Corporation was incorporated in 1991 and is headquartered in Danbury, Connecticut.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 841.11M |
| Enterprise Value | 1.14B | Income | 5.86M | Sales | 348.97M |
| Book/sh | -0.17 | Cash/sh | 0.56 | Dividend Yield | — |
| Payout | 0.00% | Employees | 591 | IPO | — |
| P/E | 136.50 | Forward P/E | 12.00 | PEG | — |
| P/S | 2.41 | P/B | -16.45 | P/C | — |
| EV/EBITDA | 19.39 | EV/Sales | 3.27 | Quick Ratio | 1.41 |
| Current Ratio | 1.71 | Debt/Eq | — | LT Debt/Eq | — |
| EPS (ttm) | 0.02 | EPS next Y | 0.23 | EPS Growth | — |
| Revenue Growth | 45.80% | Earnings | 2026-05-07 | ROA | 4.91% |
| ROE | — | ROIC | — | Gross Margin | 74.79% |
| Oper. Margin | -6.87% | Profit Margin | 1.68% | Shs Outstand | 308.10M |
| Shs Float | 302.53M | Short Float | 8.43% | Short Ratio | 4.34 |
| Short Interest | — | 52W High | 6.51 | 52W Low | 2.52 |
| Beta | 0.93 | Avg Volume | 5.29M | Volume | 3.54M |
| Target Price | $7.50 | Recom | Strong_buy | Prev Close | $2.77 |
| Price | $2.73 | Change | -1.44% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$7.50
Mean price target
2. Current target
$2.73
Latest analyst target
3. DCF / Fair value
$2.08
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$2.73
Low
$3.50
High
$10.00
Mean
$7.50
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-03-05 | main | Wedbush | Outperform → Outperform | $8 |
| 2026-02-27 | down | RBC Capital | Outperform → Sector Perform | $4 |
| 2026-02-27 | main | Wells Fargo | Overweight → Overweight | $7 |
| 2026-02-27 | main | HC Wainwright & Co. | Buy → Buy | $8 |
| 2026-02-25 | reit | HC Wainwright & Co. | Buy → Buy | $11 |
| 2026-01-26 | reit | HC Wainwright & Co. | Buy → Buy | $11 |
| 2025-11-24 | init | Truist Securities | — → Buy | $9 |
| 2025-11-11 | main | RBC Capital | Outperform → Outperform | $8 |
| 2025-11-11 | main | Wells Fargo | Overweight → Overweight | $8 |
| 2025-10-13 | reit | HC Wainwright & Co. | Buy → Buy | $11 |
| 2025-09-18 | reit | HC Wainwright & Co. | Buy → Buy | $11 |
| 2025-09-05 | main | Oppenheimer | Outperform → Outperform | $15 |
| 2025-09-03 | main | Wells Fargo | Overweight → Overweight | $10 |
| 2025-09-02 | main | HC Wainwright & Co. | Buy → Buy | $11 |
| 2025-08-26 | main | RBC Capital | Outperform → Outperform | $8 |
| 2025-08-07 | main | RBC Capital | Outperform → Outperform | $7 |
| 2025-07-25 | reit | HC Wainwright & Co. | Buy → Buy | $9 |
| 2025-07-23 | main | RBC Capital | Outperform → Outperform | $8 |
| 2025-04-10 | init | Mizuho | — → Outperform | $12 |
| 2024-12-20 | init | Wells Fargo | — → Overweight | $9 |
- Why MannKind (MNKD) Is Down 40.8% After Earnings Miss And New Tyvaso DPI Rival Appears - simplywall.st Sun, 01 Mar 2026 08
- Why MannKind Stock Tumbled on Thursday - The Motley Fool hu, 26 Feb 2026 08
- MannKind stock tumbles 37% on United Therapeutics inhaler news - Investing.com Wed, 25 Feb 2026 08
- MannKind closes note deal with $35.5M cash and 569,023 shares - Stock Titan hu, 05 Mar 2026 21
- Wedbush Remains Bullish on MannKind Corporation (MNKD) - MSN Mon, 16 Mar 2026 05
- Avoro Capital Advisors LLC Lowers Position in MannKind Corporation $MNKD - MarketBeat Sat, 14 Mar 2026 07
- MannKind Corporation (MNKD) Reveals 2026 Growth Drivers - Yahoo Finance Mon, 19 Jan 2026 08
- Insider Stock Purchases: March 11, 2026 - Quiver Quantitative Wed, 11 Mar 2026 18
- MannKind Announces Settlement of Convertible Senior Notes - GlobeNewswire hu, 05 Mar 2026 08
- MNKD MannKind (NASDAQ): Shares slide 36.82% to $3.50 pre-earnings, catalyst to watch - Meyka hu, 26 Feb 2026 08
- MannKind CEO and CFO to speak at two Miami healthcare events - Stock Titan Wed, 04 Mar 2026 08
- MannKind (NASDAQ:MNKD) Rating Lowered to Strong Sell at Zacks Research - MarketBeat Fri, 13 Mar 2026 10
- MannKind Corp stock hits 52-week low at $3.36 - Investing.com Wed, 25 Feb 2026 08
- A Look At MannKind (MNKD) Valuation After New United Therapeutics Inhaler Raises Royalty Concerns - simplywall.st Mon, 02 Mar 2026 08
- How The MannKind (MNKD) Investment Story Is Shifting With New Risks And 2026 Catalysts - Yahoo Finance Sun, 08 Mar 2026 08
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 100000 | 259000 | — | Purchase at price 2.59 per share. | CASTAGNA MICHAEL E | Chief Executive Officer | — | 2026-03-10 00:00:00 | D |
| 1 | 12000 | 39240 | — | Stock Award(Grant) at price 3.27 per share. | SHANNON JAMES SAMUEL | Director | — | 2026-02-27 00:00:00 | D |
| 2 | 15290 | 49998 | — | Stock Award(Grant) at price 3.27 per share. | TROSS STUART A | Officer | — | 2026-02-27 00:00:00 | D |
| 3 | 15290 | 49998 | — | Stock Award(Grant) at price 3.27 per share. | CASTAGNA MICHAEL E | Chief Executive Officer | — | 2026-02-27 00:00:00 | D |
| 4 | 5000 | 16350 | — | Stock Award(Grant) at price 3.27 per share. | PRENTISS CHRISTOPHER B. | Chief Financial Officer | — | 2026-02-27 00:00:00 | D |
| 5 | 35000 | 114450 | — | Stock Award(Grant) at price 3.27 per share. | HOOPER ANTHONY C | Director | — | 2026-02-27 00:00:00 | D |
| 6 | 47006 | 297548 | — | Sale at price 6.33 per share. | TROSS STUART A | Officer | — | 2026-01-08 00:00:00 | D |
| 7 | 44171 | — | — | Stock Gift at price 0.00 per share. | CASTAGNA MICHAEL E | Chief Executive Officer | — | 2025-12-24 00:00:00 | D |
| 8 | 65804 | 299408 | — | Conversion of Exercise of derivative security at price 4.55 per share. | CASTAGNA MICHAEL E | Chief Executive Officer | — | 2025-12-17 00:00:00 | D |
| 9 | 65804 | 395482 | — | Sale at price 6.01 per share. | CASTAGNA MICHAEL E | Chief Executive Officer | — | 2025-12-17 00:00:00 | D |
Financials
| Line Item | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | -2.97M | -1.23M | -438.06K | 0.00 |
| TaxRateForCalcs | 0.21 | 0.10 | 0.21 | 0.00 |
| NormalizedEBITDA | 65.67M | 88.49M | 21.20M | -60.20M |
| TotalUnusualItems | -14.16M | -12.83M | -2.09M | 3.88M |
| TotalUnusualItemsExcludingGoodwill | -14.16M | -12.83M | -2.09M | 3.88M |
| NetIncomeFromContinuingOperationNetMinorityInterest | 5.86M | 27.59M | -11.94M | -87.40M |
| ReconciledDepreciation | 12.28M | 7.37M | 4.54M | 6.31M |
| ReconciledCostOfRevenue | 79.65M | 69.23M | 58.24M | 57.50M |
| EBITDA | 51.51M | 75.66M | 19.11M | -56.32M |
| EBIT | 39.23M | 68.29M | 14.58M | -62.63M |
| NetInterestIncome | -29.98M | -25.37M | -19.01M | -22.26M |
| InterestExpense | 37.82M | 37.77M | 24.95M | 24.77M |
| InterestIncome | 8.05M | 12.62M | 6.15M | 2.51M |
| NormalizedIncome | 17.05M | 39.18M | -10.29M | -91.28M |
| NetIncomeFromContinuingAndDiscontinuedOperation | 5.86M | 27.59M | -11.94M | -87.40M |
| TotalExpenses | 302.42M | 216.82M | 188.37M | 168.69M |
| TotalOperatingIncomeAsReported | 38.80M | 72.59M | 8.68M | -64.11M |
| DilutedAverageShares | 314.11M | 283.84M | 267.01M | 257.09M |
| BasicAverageShares | 305.64M | 274.42M | 267.01M | 257.09M |
| DilutedEPS | 0.02 | 0.10 | -0.04 | -0.34 |
| BasicEPS | 0.02 | 0.10 | -0.04 | -0.34 |
| DilutedNIAvailtoComStockholders | 5.86M | 27.59M | -11.94M | -87.40M |
| NetIncomeCommonStockholders | 5.86M | 27.59M | -11.94M | -87.40M |
| NetIncome | 5.86M | 27.59M | -11.94M | -87.40M |
| NetIncomeIncludingNoncontrollingInterests | 5.86M | 27.59M | -11.94M | -87.40M |
| NetIncomeContinuousOperations | 5.86M | 27.59M | -11.94M | -87.40M |
| TaxProvision | -4.46M | 2.93M | 1.56M | 0.00 |
| PretaxIncome | 1.41M | 30.52M | -10.38M | -87.40M |
| OtherIncomeExpense | -15.17M | -12.80M | -1.96M | 3.78M |
| OtherNonOperatingIncomeExpenses | -1.01M | 32.00K | 122.00K | -102.00K |
| SpecialIncomeCharges | -6.41M | -16.73M | -170.00K | 0.00 |
| OtherSpecialCharges | 20.44M | 17.20M | ||
| WriteOff | 6.41M | 1.55M | 170.00K | 0.00 |
| ImpairmentOfCapitalAssets | 0.00 | 106.00K | ||
| RestructuringAndMergernAcquisition | 0.00 | -5.26M | 0.00 | 0.00 |
| GainOnSaleOfSecurity | -7.75M | 3.91M | -1.92M | 3.88M |
| NetNonOperatingInterestIncomeExpense | -29.98M | -25.37M | -19.01M | -22.26M |
| TotalOtherFinanceCost | 207.00K | 209.00K | 208.00K | |
| InterestExpenseNonOperating | 37.82M | 37.77M | 24.95M | 24.77M |
| InterestIncomeNonOperating | 8.05M | 12.62M | 6.15M | 2.51M |
| OperatingIncome | 46.55M | 68.68M | 10.59M | -68.92M |
| OperatingExpense | 214.46M | 140.22M | 125.60M | 111.19M |
| OtherOperatingExpenses | 339.00K | |||
| DepreciationAmortizationDepletionIncomeStatement | 3.97M | 0.00 | 0.00 | |
| DepreciationAndAmortizationInIncomeStatement | 3.97M | 0.00 | 0.00 | |
| Amortization | 3.97M | 0.00 | 0.00 | |
| AmortizationOfIntangiblesIncomeStatement | 3.97M | 0.00 | 0.00 | |
| ResearchAndDevelopment | 66.35M | 45.89M | 31.28M | 19.72M |
| SellingGeneralAndAdministration | 144.13M | 94.33M | 94.31M | 91.47M |
| SellingAndMarketingExpense | 51.78M | 53.75M | 45.53M | |
| GeneralAndAdministrativeExpense | 42.54M | 37.72M | 31.89M | |
| OtherGandA | 42.54M | 37.72M | 31.89M | |
| GrossProfit | 261.01M | 208.90M | 136.19M | 42.27M |
| CostOfRevenue | 87.96M | 76.60M | 62.77M | 57.50M |
| TotalRevenue | 348.97M | 285.50M | 198.96M | 99.77M |
| OperatingRevenue | 402.92M | 339.30M | 255.39M | 99.77M |
| Line Item | 2023-12-31 | |||
|---|---|---|---|---|
| TreasurySharesNumber | 0.00 | |||
| OrdinarySharesNumber | 307.83M | 302.96M | 270.03M | 263.79M |
| ShareIssued | 307.83M | 302.96M | 270.03M | 263.79M |
| NetDebt | 279.76M | 30.22M | 203.72M | 157.02M |
| TotalDebt | 367.44M | 50.12M | 272.62M | 278.83M |
| TangibleBookValue | -443.32M | -86.01M | -249.17M | -254.12M |
| InvestedCapital | 303.62M | -42.77M | 22.53M | 22.95M |
| WorkingCapital | 120.55M | 186.47M | 269.27M | 167.60M |
| NetTangibleAssets | -443.32M | -86.01M | -249.17M | -254.12M |
| CapitalLeaseObligations | 12.80M | 14.07M | 3.92M | 5.34M |
| CommonStockEquity | -51.02M | -78.82M | -246.17M | -250.54M |
| TotalCapitalization | 267.34M | -42.77M | 2.53M | 22.95M |
| TotalEquityGrossMinorityInterest | -51.02M | -78.82M | -246.17M | -250.54M |
| StockholdersEquity | -51.02M | -78.82M | -246.17M | -250.54M |
| GainsLossesNotAffectingRetainedEarnings | 115.00K | 1.11M | 0.00 | 0.00 |
| OtherEquityAdjustments | 115.00K | 1.11M | ||
| RetainedEarnings | -3.20B | -3.20B | -3.23B | -3.22B |
| AdditionalPaidInCapital | 3.14B | 3.12B | 2.98B | 2.96B |
| CapitalStock | 3.08M | 3.03M | 2.70M | 2.64M |
| CommonStock | 3.08M | 3.03M | 2.70M | 2.64M |
| PreferredStock | 0.00 | 0.00 | 0.00 | 0.00 |
| TotalLiabilitiesNetMinorityInterest | 843.20M | 472.66M | 721.37M | 545.82M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 672.17M | 390.82M | 617.24M | 478.52M |
| OtherNonCurrentLiabilities | 303.15M | 291.97M | 294.77M | 161.95M |
| NonCurrentAccruedExpenses | 0.00 | 56.00K | 55.00K | 404.00K |
| TradeandOtherPayablesNonCurrent | 55.00K | 404.00K | ||
| NonCurrentDeferredLiabilities | 39.98M | 51.16M | 69.79M | 37.68M |
| NonCurrentDeferredRevenue | 39.98M | 51.16M | 69.79M | 37.68M |
| LongTermDebtAndCapitalLeaseObligation | 329.05M | 47.70M | 252.62M | 278.83M |
| LongTermCapitalLeaseObligation | 10.69M | 11.64M | 3.92M | 5.34M |
| LongTermDebt | 318.36M | 36.05M | 248.70M | 273.49M |
| CurrentLiabilities | 171.03M | 81.84M | 104.12M | 67.30M |
| OtherCurrentLiabilities | 51.29M | 26.70M | 28.94M | 23.68M |
| CurrentDeferredLiabilities | 15.33M | 12.41M | 10.51M | 3.04M |
| CurrentDeferredRevenue | 15.33M | 12.41M | 9.09M | 1.73M |
| CurrentDebtAndCapitalLeaseObligation | 38.39M | 2.42M | 20.00M | 9.56M |
| CurrentCapitalLeaseObligation | 2.11M | 2.42M | ||
| CurrentDebt | 36.28M | 20.00M | 9.56M | 6.98M |
| OtherCurrentBorrowings | 36.28M | 20.00M | 9.56M | 6.98M |
| CurrentProvisions | 291.00K | 804.00K | 601.00K | 1.01M |
| PayablesAndAccruedExpenses | 65.73M | 39.50M | 44.07M | 39.57M |
| CurrentAccruedExpenses | 56.69M | 32.71M | 32.93M | 28.52M |
| InterestPayable | 2.15M | 303.00K | 2.15M | 2.20M |
| Payables | 9.03M | 6.79M | 11.14M | 11.05M |
| TotalTaxPayable | 49.00K | 1.56M | 0.00 | |
| IncomeTaxPayable | 49.00K | 1.56M | 0.00 | |
| AccountsPayable | 9.03M | 6.79M | 9.58M | 11.05M |
| TotalAssets | 792.18M | 393.84M | 475.20M | 295.28M |
| TotalNonCurrentAssets | 500.60M | 125.54M | 101.81M | 60.39M |
| OtherNonCurrentAssets | 20.87M | 27.49M | 7.43M | 9.72M |
| InvestmentsAndAdvances | 5.01M | 5.48M | 7.16M | 1.96M |
| InvestmentinFinancialAssets | 5.01M | 5.48M | 7.16M | 1.96M |
| HeldToMaturitySecurities | 7.16M | 1.96M | 56.62M | |
| AvailableForSaleSecurities | 5.01M | 5.48M | ||
| GoodwillAndOtherIntangibleAssets | 392.29M | 7.20M | 3.00M | 3.58M |
| OtherIntangibleAssets | 324.70M | 5.26M | 1.07M | 1.15M |
| Goodwill | 67.59M | 1.93M | 1.93M | 2.43M |
| NetPPE | 82.42M | 85.36M | 84.22M | 45.13M |
| AccumulatedDepreciation | -113.91M | -106.68M | -101.54M | -98.56M |
| GrossPPE | 196.34M | 192.04M | 185.76M | 143.69M |
| ConstructionInProgress | 6.40M | 6.15M | 49.00M | 16.71M |
| MachineryFurnitureEquipment | 80.69M | 76.81M | 72.14M | 69.76M |
| BuildingsAndImprovements | 108.38M | 108.20M | 63.75M | 56.34M |
| LandAndImprovements | 875.00K | 875.00K | 875.00K | 875.00K |
| Properties | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 291.58M | 268.31M | 373.39M | 234.90M |
| OtherCurrentAssets | 46.55M | 31.36M | 34.85M | 25.48M |
| RestrictedCash | 0.00 | |||
| PrepaidAssets | 3.48M | |||
| Inventory | 35.31M | 27.89M | 28.55M | 21.77M |
| FinishedGoods | 9.47M | 11.04M | 8.64M | 2.22M |
| WorkInProcess | 11.09M | 10.66M | 13.65M | 13.81M |
| RawMaterials | 14.76M | 6.18M | 6.26M | 5.74M |
| Receivables | 38.37M | 11.80M | 14.90M | 16.80M |
| AccountsReceivable | 38.37M | 11.80M | 14.90M | 16.80M |
| AllowanceForDoubtfulAccountsReceivable | -13.60M | -13.04M | -8.84M | -6.64M |
| GrossAccountsReceivable | 51.97M | 24.85M | 23.74M | 23.45M |
| CashCashEquivalentsAndShortTermInvestments | 171.35M | 197.26M | 295.10M | 170.85M |
| OtherShortTermInvestments | 96.46M | 150.92M | 56.62M | 101.08M |
| CashAndCashEquivalents | 74.88M | 46.34M | 238.48M | 69.77M |
| CashFinancial | 124.18M |
| Line Item | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| FreeCashFlow | 13.69M | 32.82M | -8.35M | -88.27M |
| RepaymentOfDebt | 0.00 | -133.17M | -6.67M | 0.00 |
| IssuanceOfDebt | 325.00M | 0.00 | 0.00 | 0.00 |
| IssuanceOfCapitalStock | 0.00 | 0.00 | 6.89M | 19.79M |
| CapitalExpenditure | -4.57M | -9.69M | -42.44M | -7.59M |
| InterestPaidSupplementalData | 14.72M | 17.51M | 18.28M | 8.85M |
| IncomeTaxPaidSupplementalData | 1.71M | 4.26M | 0.00 | |
| EndCashPosition | 75.63M | 47.08M | 238.48M | 69.77M |
| BeginningCashPosition | 47.08M | 238.48M | 69.77M | 124.18M |
| ChangesInCash | 28.55M | -191.40M | 168.71M | -54.42M |
| FinancingCashFlow | 315.10M | -137.27M | 136.61M | 21.39M |
| CashFlowFromContinuingFinancingActivities | 315.10M | -137.27M | 136.61M | 21.39M |
| NetOtherFinancingCharges | -11.89M | -7.24M | 134.57M | -1.17M |
| ProceedsFromStockOptionExercised | 1.99M | 3.14M | 1.82M | 2.77M |
| NetCommonStockIssuance | 0.00 | 0.00 | 6.89M | 19.79M |
| CommonStockIssuance | 0.00 | 0.00 | 6.89M | 19.79M |
| NetIssuancePaymentsOfDebt | 325.00M | -133.17M | -6.67M | 0.00 |
| NetShortTermDebtIssuance | -11.00M | |||
| ShortTermDebtPayments | -11.00M | |||
| NetLongTermDebtIssuance | 325.00M | -133.17M | -6.67M | 0.00 |
| LongTermDebtPayments | 0.00 | -133.17M | -6.67M | 0.00 |
| LongTermDebtIssuance | 325.00M | 0.00 | 0.00 | 0.00 |
| InvestingCashFlow | -304.80M | -96.65M | -1.99M | 4.87M |
| CashFlowFromContinuingInvestingActivities | -304.80M | -96.65M | -1.99M | 4.87M |
| NetOtherInvestingChanges | -10.00M | 396.00K | 382.00K | |
| NetInvestmentPurchaseAndSale | 57.51M | -86.96M | 40.45M | 27.80M |
| SaleOfInvestment | 215.31M | 193.84M | 119.55M | 107.34M |
| PurchaseOfInvestment | -157.80M | -280.80M | -79.09M | -79.54M |
| NetBusinessPurchaseAndSale | -347.74M | 0.00 | 0.00 | -15.34M |
| PurchaseOfBusiness | -347.74M | 0.00 | 0.00 | -15.34M |
| NetIntangiblesPurchaseAndSale | 0.00 | 0.00 | ||
| PurchaseOfIntangibles | 0.00 | 0.00 | ||
| NetPPEPurchaseAndSale | -4.57M | -9.69M | -42.44M | -7.59M |
| PurchaseOfPPE | -4.57M | -9.69M | -42.44M | -7.59M |
| OperatingCashFlow | 18.25M | 42.51M | 34.09M | -80.68M |
| CashFlowFromContinuingOperatingActivities | 18.25M | 42.51M | 34.09M | -80.68M |
| ChangeInWorkingCapital | -50.88M | -36.47M | 16.73M | -24.05M |
| ChangeInOtherWorkingCapital | -8.26M | -15.31M | 39.46M | 14.10M |
| ChangeInOtherCurrentLiabilities | -873.00K | -4.98M | -11.81M | -9.02M |
| ChangeInOtherCurrentAssets | -1.91M | -3.57M | 263.00K | 523.00K |
| ChangeInPayablesAndAccruedExpense | -18.42M | -5.49M | 5.13M | 3.37M |
| ChangeInAccruedExpense | 3.26M | -2.70M | 6.61M | -723.00K |
| ChangeInInterestPayable | 0.00 | 0.00 | -4.92M | |
| ChangeInPayable | -21.68M | -2.79M | -1.47M | 4.10M |
| ChangeInAccountPayable | -16.71M | -2.79M | -1.47M | 4.10M |
| ChangeInTaxPayable | -4.97M | 0.00 | 0.00 | |
| ChangeInIncomeTaxPayable | -4.97M | 0.00 | 0.00 | |
| ChangeInPrepaidAssets | -10.03M | -6.57M | -7.32M | -15.55M |
| ChangeInInventory | -6.62M | -3.20M | -11.35M | -5.67M |
| ChangeInReceivables | -4.76M | 2.65M | 2.35M | -11.81M |
| ChangesInAccountReceivables | -4.76M | 2.65M | 2.35M | -11.81M |
| OtherNonCashItems | 4.89M | 5.82M | 1.38M | 11.99M |
| StockBasedCompensation | 24.20M | 21.36M | 17.65M | 13.45M |
| AssetImpairmentCharge | 10.40M | 3.85M | 4.57M | 2.20M |
| AmortizationOfSecurities | -2.65M | -5.09M | -925.00K | 707.00K |
| DepreciationAmortizationDepletion | 12.28M | 7.37M | 4.54M | 6.31M |
| DepreciationAndAmortization | 12.28M | 7.37M | 4.54M | 6.31M |
| Depreciation | 12.28M | 7.37M | 4.54M | 6.31M |
| OperatingGainsLosses | 14.16M | 18.09M | 2.09M | -3.88M |
| GainLossOnInvestmentSecurities | 6.41M | 1.55M | 170.00K | 932.00K |
| NetForeignCurrencyExchangeGainLoss | 7.75M | -3.91M | 1.92M | -4.81M |
| GainLossOnSaleOfPPE | 565.00K | 0.00 | 0.00 | |
| NetIncomeFromContinuingOperations | 5.86M | 27.59M | -11.94M | -87.40M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for MNKD
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|